Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy, such as thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well thiotepa works together with radiation therapy in treating young patients with newly diagnosed malignant brain tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer and Leukaemia Group
• Treatments: Thiotepa

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following high-grade (malignant) astrocytic tumors:

• Anaplastic astrocytoma

• Glioblastoma

• Giant cell glioblastoma

• Gliosarcoma

• Any anatomical site except brain stem

• Newly diagnosed disease

• Has undergone tumor biopsy or surgical resection within the past 2 weeks

• Patients with post-operative residual disease (grade III or IV) are eligible

• Post-operative imaging of tumor within 72 hours of surgery

• Patients with no imageable post-operative disease are not eligible

• No neurological deterioration within 3 days of study treatment

• Increasing requirement for steroids to control symptoms of intracranial pressure is considered evidence of neurological deterioration

PATIENT CHARACTERISTICS:

• Lansky play score 40-100%

• Absolute neutrophil count > 1,000/mm^3

• Platelet count > 100,000/mm^3

• Creatinine ≥ 1.5 times upper limit of normal

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy or radiotherapy